Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT06912282
Recruiting Not applicable

Bilateral Single-Electrode VO Combined With STN-DBS for Treating Meige Syndrome

NCT06912282 · tracked via the Priya Life Science China tracker
Sponsor
Huashan Hospital
Phase
Not applicable
Started
2025-03-06
Last updated
2025-04-04

Condition(s) studied

Meige Syndrome

Investigational drug(s) / intervention(s)

deep brain stimulation

deep brain stimulation: bilateral single-electrode VO combined with STN target implantation

Study summary

Meige syndrome is a rare and debilitating movement disorder characterized by blepharospasm, oromandibular dystonia, and cervical muscle contractions, often refractory to pharmacological therapies. Deep brain stimulation (DBS), initially developed to treat essential tremor and Parkinson's disease, has been explored in recent years as a potential treatment for various dystonias, including Meige's syndrome. This clinical study aims to evaluate the safety and efficacy of bilateral single-electrode ventralis oralis (VO) nucleus stimulation combined with subthalamic nucleus deep brain stimulation (STN-DBS) in patients with Meige syndrome.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Must meet the clinical diagnostic criteria for Meige syndrome * Only includes patients with: Blepharospasm-type Meige syndrome and Blepharospasm with lower jaw muscle dystonia-type * All patients must have undergone at least one year of systematic and standard treatment prior to surgery Exclusion Criteria: * History of neurological diseases other than Meige syndrome * Severe cognitive impairment * Severe psychiatric disorders

Primary outcome measure(s)

  • Improvement of primary symptoms — 1 year after stimulation
    Scale title: Burke-Fahn-Marsden Dystonia Rating Scale Section I: Motor subscale (0-120) Section II: Disability scale (0-30) Higher scores: Indicate worse outcomes (more severe dystonia symptoms).

Trial sites (1)

FacilityCityRegionStatus
Huashan Hospital, Fudan University. Shanghai Shanghai Municipality Recruiting

More Huashan Hospital trials in China

Real-World Study of Enarodustat for Anemia in Non-Dialysis CKD Patients Recruiting
The Impact of Probiotic Intervention on the Gut Microbiota and Bowel Function Recruiting
The Role of B7-H4 in Tumor Vaccine Recruiting
Precision Diagnosis and Prospective Cohort Study for Myasthenia Gravis: Multicenter Analysis in China Recruiting
Clinical Multimodal Surveillance of Respiratory Syndrome Pathogens Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06912282 on ClinicalTrials.gov ↗ ← All trials in China